Brief: Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
02/11/2023 12:40
Nov 2 (Reuters) - Vaxart Inc VXRT.O :
* VAXART DOSES FIRST SUBJECT IN PHASE 1 TRIAL OF ITS
NOROVIRUS
VACCINE CANDIDATE IN LACTATING MOTHERS
Source text for Eikon: ID:nGNXzXXNc
Further company coverage: VXRT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts